Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:HCM

HUTCHMED 6/4/2026 Earnings Report

HUTCHMED logo
$11.17 -0.14 (-1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$11.17 +0.00 (+0.04%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

HUTCHMED EPS Results

Actual EPS
N/A
Consensus EPS
-$0.36
Beat/Miss
N/A
One Year Ago EPS
N/A

HUTCHMED Revenue Results

Actual Revenue
N/A
Expected Revenue
$80.92 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

HUTCHMED Announcement Details

Quarter
Date
6/4/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

HUTCHMED Earnings Headlines

HUTCHMED (NASDAQ:HCM) Share Price Crosses Below 50-Day Moving Average - Time to Sell?
June 3 at 3:55 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30815579
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3299860/0/en/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting.html
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
June 4 at 1:00 AM  |  Porter & Company (Ad)
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally ...
May 21, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/innovent-hutchmed-jointly-announce-nmpa-100000286.html
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally ...
May 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/hutchmed-and-innovent-jointly-announce-nmpa-approval-for-elunate-fruquintinib-in-combination-with-tyvyt-sintilimab-injection-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-1036182841
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299110/0/en/hutchmed-and-innovent-jointly-announce-nmpa-approval-for-elunate-fruquintinib-in-combination-with-tyvyt-sintilimab-injection-for-the-treatment-of-patients-with-locally-advanced-or-.html
See More HUTCHMED Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HUTCHMED? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HUTCHMED and other key companies, straight to your email.

About HUTCHMED

HUTCHMED (NASDAQ:HCM) (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer. Its clinical pipeline features both small molecules and monoclonal antibodies targeting receptor tyrosine kinases, immuno-oncology checkpoints and novel pathways, with ongoing trials in the United States, Europe and Asia. The company has established strategic partnerships and licensing collaborations with leading global pharmaceutical and biotechnology firms to co-develop and co-commercialize its assets.

Founded in 2000 as Hutchison MediPharma and rebranded as HUTCHMED in 2018, the company is headquartered in Hong Kong, with research and development centers in Shanghai and Suzhou, China. HUTCHMED maintains commercial operations across mainland China and extends its clinical research infrastructure to the United States and Europe. Guided by an experienced leadership team with backgrounds in drug discovery, clinical development and commercial strategy, HUTCHMED continues to pursue its goal of delivering innovative medicines to patients worldwide.

View HUTCHMED Profile
Earnings Tools